PDE4A and Alzheimer disease: Chovatiya and Paller, and Kader et al. report that in May 2016, the new topical PDE4 inhibitor crisaborole 2% ointment received a license to treat mild-to-moderate AD in people two years of age and older [5-74]; the permission was expanded to include infants as young as three months in March 2020.